ASND

Ascendis Pharma A/S

275.39

Nov 13 • 3:59 PM ET +8.32 (3.12%)

275.39

Aftermarket • 7:30 PM ET 0.00 (0.00%)

Healthcare Biotechnology Denmark Large NASD

Nov 13, 8:32 PMPost-earnings analyst target hikes lift Ascendis Pharma 3.1% during Friday’s regular session

Peers: BMRN BBIO MBX RYTM NVO INSM NBIX RARE ALNY PFE

| Held by: TCAF IBB IWP IWR IWF SQS VONG FXH SPDW COWG

Scroll to Statements

Index	RUI
Market Cap	18.08B
Enterprise Value	17.50B
Income	1.02B
Sales	1.40B
Book/sh	25.98
Cash/sh	16.68
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	-
IPO	Jan 28, 2015

P/E	17.73
Forward P/E	24.81
PEG	-
P/S	12.95
P/B	10.60
P/C	16.51
P/FCF	30.24
EV/EBITDA	63.03
EV/Sales	12.53
Quick Ratio	2.29
Current Ratio	2.89
Debt/Eq	0.30
LT Debt/Eq	0.25
Option/Short	Yes / Yes

EPS (ttm)	15.54
EPS next Y	11.10
EPS next Q	1.77
EPS this Y	503.01%
EPS next Y	-33.74%
EPS next 5Y	-
EPS past 3/5Y	27.03% 14.76%
Sales past 3/5Y	147.23% 152.45%
EPS Y/Y TTM	484.66%
Sales Y/Y TTM	93.79%
EPS Q/Q	205.59%
Sales Q/Q	70.35%
Earnings	Nov 12 BMO
EPS/Sales Surpr.	35.94% 1.58%

Insider Own	1.16%
Insider Trans	0.00%
Inst Own	100.49%
Inst Trans	1.57%
ROA	49.73%
ROE	136.42%
ROIC	47.95%
Gross Margin	90.61%
Oper. Margin	18.36%
Profit Margin	73.26%
SMA20	9.72%
SMA50	13.48%
SMA200	14.82%
Trades

Shs Outstand	65.60M
Shs Float	64.84M
Short Float	4.62%
Short Ratio	4.08
Short Interest	3.00M
52W High	282.15 -2.40%
52W Low	188.07 46.43%
Volatility	3.26% 2.54%
ATR (14)	7.14
RSI (14)	74.71
Beta	0.38
Rel Volume	1.12
Avg Volume	735.53K
Volume	825,888

Perf Week	7.23%
Perf Month	21.52%
Perf Quarter	11.31%
Perf Half Y	14.51%
Perf YTD	29.15%
Perf Year	33.39%
Perf 3Y	207.94%
Perf 5Y	76.85%
Perf 10Y	1312.98%
Recom	1.18
Target Price	316.26
Prev Close	267.07
Price	275.39
Change %	3.12%

Consensus

Strong Buy

Avg. Price Target

$316.26

Implied Upside

+14.8%

Analysts14incl. previous ratings

Rating Distribution12 Buy · 2 Hold · 0 Sell

Date	Action	Analyst	Rating Change	Price Target Change	Implied Upside
Sep 15, 2026	Downgrade	RRaymond James	Strong Buy → Outperform	$287	+4.2%
Aug 27, 2026	Initiated	HH.C. Wainwright	Buy	$345	+25.3%
Aug 19, 2026	Initiated	BBMO Capital Markets	Outperform	$319	+15.8%
May 19, 2026	Initiated	CCitigroup	Buy	$355	+28.9%
Mar 16, 2026	Resumed	JJefferies	Buy
Jan 28, 2026	Initiated	BBarclays	Overweight	$342	+24.2%
Nov 18, 2025	Initiated	WWolfe Research	Peer Perform	$255	-7.4%
Oct 17, 2025	Initiated	RRaymond James	Strong Buy	$271	-1.6%
Jul 03, 2025	Resumed	MMorgan Stanley	Overweight	$250	-9.2%
May 05, 2025	Upgrade	MMorgan Stanley	Equal-Weight → Overweight	$250	-9.2%
Apr 16, 2025	Initiated	RRBC Capital Mkts	Outperform	$205	-25.6%
Jan 07, 2025	Initiated	UUBS	Buy	$196	-28.8%
Sep 05, 2024	Upgrade	OOppenheimer	Perform → Outperform	$180	-34.6%
Jun 25, 2024	Upgrade	TTD Cowen	Hold → Buy	$156 → $175	-36.5%
May 31, 2024	Initiated	SStifel	Buy	$200	-27.4%
Dec 20, 2023	Initiated	JJefferies	Buy	$150	-45.5%
Jun 14, 2023	Resumed	CCredit Suisse	Neutral	$89	-67.7%
Apr 05, 2023	Downgrade	OOppenheimer	Outperform → Perform
Apr 04, 2023	Downgrade	MMorgan Stanley	Overweight → Equal-Weight	$151 → $108	-60.8%
Apr 03, 2023	Downgrade	CCredit Suisse	Outperform → Neutral

Nov-12-26 03:55PM	Ascendis Pharma earnings analysis: questions answered and next catalysts (Investing.com)
10:41AM	Ascendis Pharma Beats As YORVIPATH Scales And Margins Jump, But The 42% Margin Flatters The Run Rate (Earnings Whispers)
07:30AM	Ascendis Pharma Reports Third Quarter 2026 Financial Results (GlobeNewswire)
Nov-10-26 04:01PM	Ascendis Pharma to Participate in the Jefferies London Healthcare Conference (GlobeNewswire)
Nov-06-26 02:28PM	Ascendis Faces Its First Clean Quarter After PRV Windfall As UVWell Ramp Takes Center Stage (Earnings Whispers)
08:00AM	Loading…
08:00AM	Once-Weekly TransCon CNP (Navepegritide) to Receive 10 Years of Market Exclusivity Upon Approval in the European Union (GlobeNewswire)
Nov-05-26 04:01PM	Ascendis to Report Third Quarter 2026 Financial Results and Provide Business Update on November 12, 2026 (GlobeNewswire)
Oct-26-26 08:00AM	TransCon PTH (Palopegteriparatide) Demonstrates Sustained, Clinically Meaningful Improvements in Kidney Function in Adults with Hypoparathyroidism Treated Up to 5 Years (GlobeNewswire)
Oct-20-26 03:27PM	RBC Capital names top healthcare stocks as sector upgraded to overweight (Investing.com)
Oct-16-26 04:30PM	ASND Shares Shrug Off Positive European Opinion For FDA-Approved Achondroplasia Drug (Stocktwits)
08:29AM	Once-Weekly TransCon CNP (Navepegritide) Receives Positive CHMP Opinion for the Treatment of Achondroplasia in Children (GlobeNewswire)
Oct-06-26 09:15AM	Ascendis to Share Latest Advances in Hypoparathyroidism and Achondroplasia Programs at ASBMR 2026 (GlobeNewswire)
Sep-15-26 09:35AM	Ulta Beauty, Etsy upgraded: Wall Street's top analyst calls (The Fly) -9.49%
Sep-14-26 06:00PM	Ascendis to Regain Rights to TransCon Technology in Metabolic and Cardiovascular Diseases (GlobeNewswire)
06:00PM	Ascendis Announces Planned $400 Million Share Repurchase Program (GlobeNewswire)
04:01PM	Loading…
Sep-09-26 04:01PM	First Infant Data from Ascendis Trial of Once-Weekly TransCon CNP (Navepegritide) Presented at ESPE 2026 (GlobeNewswire)
Sep-08-26 04:01PM	Ascendis Pharma to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference (GlobeNewswire)
Sep-07-26 07:00AM	Ascendis to Share Its Latest Endocrinology Rare Disease Data at ESPE 2026 (GlobeNewswire)
Sep-02-26 06:12AM	Teva claims success in celiac study; BioMarin, Ascendis settle patent dispute (BioPharma Dive)
Aug-31-26 01:30PM	ASND, BMRN Stocks Rise: Street Calls Patent Peace A Clean Overhang Lift, Keep Ratings Unchanged (Stocktwits) +6.10%
07:00AM	Ascendis and BioMarin Enter Binding Term Sheet for a Global Settlement and License Agreement Related to YUVIWEL (Navepegritide) (GlobeNewswire)
Aug-27-26 09:34AM	First Solar upgraded, Celsius downgraded: Wall Street's top analyst calls (The Fly)
Aug-25-26 04:01PM	Ascendis Announces Oral Presentation of Week 104 Data from Its Pivotal Trial of TransCon CNP (Navepegritide) at ISDS 2026 (GlobeNewswire)
Aug-13-26 07:09PM	Ascendis Pharma AS (ASND) (Q2 2026) Earnings Call Highlights: Revenue Doubles to EUR315 ... (GuruFocus.com)
07:30AM	Ascendis Pharma Reports Second Quarter 2026 Financial Results (GlobeNewswire)
Aug-06-26 04:01PM	Ascendis to Report Second Quarter 2026 Financial Results and Provide Business Update on August 13, 2026 (GlobeNewswire)
08:00AM	Ascendis Announces COACH Week 78 Results and Provides Update on Achondroplasia Programs and YUVIWEL Uptake in the U.S. (GlobeNewswire)
Jun-30-26 08:30AM	Children with Achondroplasia Treated with TransCon CNP Showed Continued Improvements in Lower Extremity Alignment at Week 104 of the Pivotal ApproaCH Trial (GlobeNewswire)
Jun-26-26 04:01PM	Ascendis Joins Multiple Russell U.S. Indexes, Including the Russell 3000, Russell 1000, Russell 2500 and Russell Midcap (GlobeNewswire)
Jun-25-26 04:01PM	Ascendis to Showcase Advances in Treatment of Achondroplasia at ICCBH 2026 (GlobeNewswire) +9.90%
04:00PM	Loading…
Jun-13-26 04:00PM	Phase 3 Data Show TransCon PTH Replicated Systemic Actions of Endogenous PTH Through Week 182 in Adults with Hypoparathyroidism (GlobeNewswire)
Jun-11-26 04:01PM	5-Year Phase 2 Data Show TransCon PTH Replicated Systemic Actions of Endogenous PTH in Adults with Hypoparathyroidism (GlobeNewswire)
Jun-08-26 04:59PM	Ascendis to Showcase Advances in Treatment of Rare Endocrine Diseases at ENDO 2026 (GlobeNewswire)
May-28-26 04:27PM	JPMorgan says large-cap biotech is back as profits and pipelines fuel upside (Investing.com) -5.63%
May-20-26 03:29PM	JPMorgan sees biotech sector at inflection point, resumes coverage on 14 Firms (Investing.com)
May-19-26 09:34AM	StubHub, Jazz Pharmaceuticals upgraded: Wall Street's top analyst calls (The Fly)
May-07-26 07:30AM	Ascendis Pharma Reports First Quarter 2026 Financial Results (GlobeNewswire)
May-06-26 04:01PM	New 2-Year Data from Pivotal ApproaCH Trial of TransCon CNP (Navepegritide) Show Pronounced Gains in Growth Outcomes in Children with Achondroplasia Aged =5 Years (GlobeNewswire)
Apr-30-26 04:01PM	Ascendis to Report First Quarter 2026 Financial Results and Provide Business Update on May 7, 2026 (GlobeNewswire)
Apr-21-26 04:31PM	Ascendis Announces Redemption of All $575 Million of Outstanding 2.25% Convertible Senior Notes Due 2028 (GlobeNewswire)
Apr-20-26 08:00AM	Ascendis Pharma Announces Commencement of Trading of its Ordinary Shares on Nasdaq (GlobeNewswire)
Apr-08-26 12:00PM	Ascendis Pharma to List Ordinary Shares Directly on Nasdaq (GlobeNewswire) +5.77%
08:01AM	New Data from Week 52 of the Ongoing COACH Trial Showed that TransCon hGH Accelerated TransCon CNP's Benefits Beyond Linear Growth in Children with Achondroplasia (GlobeNewswire)
Apr-06-26 04:01PM	Ascendis Receives Orphan Drug Exclusivity and Launches YUVIWEL (Navepegritide) in the United States (GlobeNewswire)
Mar-17-26 08:30AM	New InsiGHTS Trial of TransCon hGH (Lonapegsomatropin) in Turner Syndrome Demonstrated Comparable Efficacy and Safety to Daily Somatropin at Week 52 (GlobeNewswire)
Mar-16-26 08:00AM	New Two-Year Data from Pivotal ApproaCH Trial Showing Durable Benefits of TransCon CNP (Navepegritide) in Children with Achondroplasia Shared at ACMG 2026 (GlobeNewswire)
Mar-04-26 10:32PM	Ascendis Pharma Details Early Q2 YUVIWEL Launch Plan, Pricing Tease at TD Cowen Conference (MarketBeat)
09:54PM	Ascendis Pharma Maps 2026 U.S. Launch of Once-Weekly YUVIWEL After FDA Approval in Achondroplasia (MarketBeat)
01:24PM	This Biopharma Stock Flirts With Buy Point After New FDA Approval (Investor's Business Daily)
05:45AM	Ascendis Wins FDA Approval For Rare Disease Therapy (Benzinga)
Mar-02-26 08:43AM	Ascendis Pharma to Participate in the TD Cowen 46th Annual Health Care Conference (GlobeNewswire)
08:02AM	Ascendis Wins FDA Approval For Rare Disease Therapy (Benzinga)
07:22AM	Ascendis wins FDA approval of dwarfism drug (BioPharma Dive)
Feb-27-26 05:57PM	FDA Approves Once-Weekly YUVIWEL (navepegritide) for Children with Achondroplasia Aged 2 Years and Older (GlobeNewswire)
Feb-20-26 04:10AM	Ascendis Pharma (ASND) Revenue Nearly Doubles to 720M in 2025 Fueled by Core Product Growth (Insider Monkey)
Feb-12-26 12:44PM	BridgeBio Nears 52-Week High On Strong Dwarfism Trial Data, Plans FDA Filing In 2026 (Benzinga)
12:23PM	Earnings roundup: Neurocrine slumps, Alnylam battles skeptics and Ascendis eyes a competitor (BioPharma Dive)
12:03AM	Ascendis Pharma AS (ASND) Q4 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic ... (GuruFocus.com)
Feb-11-26 06:39PM	Ascendis Pharma A/S Q4 Earnings Call Highlights (MarketBeat)
04:01PM	Ascendis Pharma Reports Fourth Quarter and Full-Year 2025 Financial Results (GlobeNewswire)
Feb-04-26 04:01PM	Ascendis Pharma to Report Full Year 2025 Financial Results and Provide Business Update on February 11, 2026 (GlobeNewswire)
Jan-30-26 02:07AM	RBC Maintains Outperform Rating on Ascendis Pharma (ASND) Amid Growth Targets (Insider Monkey)
Jan-29-26 03:01PM	BofA Reiterates Buy Rating on Ascendis Pharma (ASND) While Wells Fargo Analyst Raises PT (Insider Monkey)
Jan-26-26 10:14AM	Allstate Upgraded, Amazon Downgraded: Updated Rankings on Top Blue-Chip Stocks (InvestorPlace)
Jan-15-26 01:03PM	Ascendis Pharma A/S (ASND): A Bull Case Theory (Insider Monkey)
Jan-14-26 06:14AM	Ascendis Pharma (ASND) Surges 3.0%: Is This an Indication of Further Gains? (Zacks)
Jan-12-26 07:02PM	Ascendis Pharma A/S Touts 683M Product Revenue, Feb PDUFA Catalyst at JPM Healthcare Conference (MarketBeat)
Jan-09-26 06:01PM	Ascendis Pharma Provides Business and Strategic Roadmap Update at 44th Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Jan-08-26 11:03PM	Ascendis Pharma COACH Week 52 data show combo TransCon CNP + hGH boosts growth in achondroplasia (MarketBeat)
04:01PM	Week 52 COACH Trial Topline Results Confirm Consistent and Durable Treatment Benefits in Children with Achondroplasia (ACH) (GlobeNewswire)
Jan-05-26 08:30AM	Ascendis Pharma to Participate in the 44th Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-15-25 09:42AM	Ford Upgraded, Amazon Downgraded: Updated Rankings on Top Blue-Chip Stocks (InvestorPlace)
Dec-11-25 10:37AM	Eight stock picks to play one of the healthiest corners of the market (MarketWatch)
Dec-04-25 11:10AM	The Biotech Industry Is Healthier Than Investors Think. These Are the Stocks to Watch. (Barrons.com)
Nov-26-25 05:47AM	Novartis cuts hundreds of jobs; Novos dual-acting diabetes drug heading to Phase 3 (BioPharma Dive)
Nov-25-25 06:15PM	Ascendis Announces Extension of FDA Review Period for TransCon CNP (navepegritide) for Children with Achondroplasia (GlobeNewswire)
Nov-17-25 04:01PM	Results of Pivotal ApproaCH Trial of TransCon CNP (Navepegritide) in Children with Achondroplasia Published in JAMA Pediatrics (GlobeNewswire) +5.95%
Nov-13-25 12:00AM	Ascendis Pharma AS (ASND) Q3 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic ... (GuruFocus.com)
Nov-12-25 04:01PM	Ascendis Pharma Reports Third Quarter 2025 Financial Results (GlobeNewswire)
07:54AM	MDT Q2 Earnings Preview: Cardiovascular Unit Likely to Boost Growth (Zacks)
05:25AM	Cisco Systems headlines earnings slate (MarketWatch)
03:51AM	Stock Market Today: Dow consolidates after 3-day 1,000-point surge to record high, S&P 500 and Nasdaq called higher as Treasury yields dip; Cisco earnings on tap. (MarketWatch)
Nov-10-25 11:21AM	Are These 4 Biotech Stocks Set to Beat Q3 Earnings Estimates? (Zacks)
Nov-07-25 08:30AM	New Pooled 3-Year Analysis Confirms Sustained, Clinically Meaningful Improvements in Renal Function for TransCon PTH (Palopegteriparatide)-Treated Adults with Hypoparathyroidism (GlobeNewswire)
Nov-05-25 04:01PM	Ascendis Pharma to Report Third Quarter 2025 Financial Results and Provide Business Update on November 12, 2025 (GlobeNewswire) -5.04%
Nov-03-25 04:01PM	3-Year Renal Data in Adults with Hypoparathyroidism Treated with TransCon PTH (Palopegteriparatide) to Be Shared at Kidney Week 2025 (GlobeNewswire)
Oct-13-25 12:29PM	Walt Disney Upgraded, Southwest Airlines Downgraded: Updated Rankings on Top Blue-Chip Stocks (InvestorPlace)
Oct-08-25 04:01PM	Ascendis Submits Marketing Authorisation Application to the European Medicines Agency for TransCon CNP for Treatment of Children with Achondroplasia (GlobeNewswire)
Oct-07-25 09:40AM	Arcus Biosciences (RCUS) Soars 8.5%: Is Further Upside Left in the Stock? (Zacks)
Oct-02-25 01:35AM	UBS Maintains Buy on Ascendis (ASND), Sees Upside from Yorvipath Data (Insider Monkey)
Sep-24-25 02:12AM	Bank of America Securities Reiterates a Buy on Ascendis Pharma (ASND) (Insider Monkey)
Sep-15-25 12:15PM	Top 3 Biotech Stocks to Watch According to BofA Global Research (Investing.com)
Sep-14-25 01:16AM	Morgan Stanley Remains Bullish on Ascendis Pharma (ASND) (Insider Monkey)
Sep-02-25 04:01PM	Ascendis to Share Latest Endocrinology Rare Disease Data in 3 Oral Presentations at ASBMR 2025 (GlobeNewswire)
Aug-28-25 04:01PM	Ascendis Pharma to Participate in the 2025 Wells Fargo Healthcare Conference (GlobeNewswire)
Aug-12-25 10:56AM	Skeletal Dysplasia Market Growth Analysis 2025-2030 Featuring BioMarin Pharma, BridgeBio Pharma, Ascendis Pharma, Ipsen, QED Therapeutics and Other Major Players (GlobeNewswire)
Aug-07-25 04:01PM	Ascendis Pharma Reports Second Quarter 2025 Financial Results (GlobeNewswire)
Jul-31-25 04:01PM	Ascendis Pharma to Report Second Quarter 2025 Financial Results and Provide Business Update on August 7, 2025 (GlobeNewswire)
Jul-28-25 07:00AM	FDA Approves SKYTROFA (Lonapegsomatropin-tcgd) for the Once-Weekly Treatment of Adults with Growth Hormone Deficiency (GlobeNewswire)
Jul-24-25 11:47PM	Ascendis Pharma A/S (ASND) Delivers Positive Trial Results for Hypoparathyroidism Treatment (Insider Monkey)

Show Previous News

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Bodenhoff Mads	SVP & PAO	Sep 08 '26	Option Exercise	110.00	3,000	330,000	3,000	Sep 09 05:04 PM
Bodenhoff Mads	SVP & PAO	Sep 08 '26	Sale	270.19	3,000	810,570	0	Sep 09 05:04 PM
Bodenhoff Mads	Officer	Sep 08 '26	Proposed Sale	270.19	3,000	810,563		Sep 08 04:16 PM
HOLTUG LARS	Director	Sep 02 '26	Sale	264.13	236	62,335	4,000	Sep 03 04:09 PM
HOLTUG LARS	Director	Sep 02 '26	Proposed Sale	264.13	236	62,335		Sep 02 12:52 PM
BIENAIME JEAN JACQUES	Director	Aug 14 '26	Buy	246.33	2,000	492,654	2,900	Aug 18 09:02 PM
SMITH SCOTT THOMAS	EVP & Chief Financial Officer	Jun 02 '26	Buy	219.00	100	21,900	4,367	Jun 02 04:25 PM
BIENAIME JEAN JACQUES	Director	May 29 '26	Buy	223.12	500	111,562	900	Jun 01 04:11 PM
SMITH SCOTT THOMAS	EVP & Chief Financial Officer	May 29 '26	Buy	223.32	250	55,830	4,267	Jun 01 04:10 PM
BIENAIME JEAN JACQUES	Director	May 26 '26	Buy	237.80	400	95,120	400	May 27 04:05 PM
JENSEN FLEMMING STEEN	See Remarks	May 11 '26	Sale	238.49	19,460	4,641,021	0	May 12 04:08 PM
JENSEN FLEMMING STEEN	Officer	May 11 '26	Proposed Sale	238.49	19,460	4,641,022		May 11 03:36 PM
SINGEL STINA	Officer	Mar 09 '26	Proposed Sale	240.00	3,782	907,680		Mar 09 05:30 PM
Bodenhoff Mads	Officer	Mar 06 '26	Proposed Sale	237.53	10,000	2,375,308		Mar 06 04:21 PM
Shu Aimee	Officer	Mar 05 '26	Proposed Sale	235.81	5,583	1,316,555		Mar 05 05:20 PM
SMITH SCOTT THOMAS	Officer	Mar 05 '26	Proposed Sale	240.00	10,000	2,400,000		Mar 05 05:07 PM
Jan Moller Mikkelsen	CEO	Mar 05 '26	Proposed Sale	241.38	94,000	22,689,720		Mar 05 05:04 PM
Morrison Lisa	Officer	Mar 04 '26	Proposed Sale	236.34	10,105	2,388,195		Mar 04 04:58 PM
Shu Aimee	Officer	Mar 04 '26	Proposed Sale	239.22	7,290	1,743,914		Mar 04 10:54 AM
Fairey William	Director	Mar 02 '26	Proposed Sale	242.09	1,800	435,762		Mar 02 05:01 PM
IMANI SIHAM	Director	Mar 02 '26	Proposed Sale	242.09	1,800	435,762		Mar 02 04:59 PM
SMITH SCOTT THOMAS	Officer	Mar 02 '26	Proposed Sale	242.09	18,349	4,442,109		Mar 02 04:56 PM
JENSEN MICHAEL WOLFF	Officer	Mar 02 '26	Proposed Sale	242.09	18,349	4,442,109		Mar 02 04:52 PM
Bodenhoff Mads	Officer	Mar 02 '26	Proposed Sale	242.09	6,872	1,663,642		Mar 02 04:44 PM
PEDERSEN ANNI LOTTE KIRSTINE S	Officer	Mar 02 '26	Proposed Sale	242.09	10,800	2,614,572		Mar 02 04:40 PM
Morrison Lisa	Director	Mar 02 '26	Proposed Sale	242.09	2,100	508,389		Mar 02 04:35 PM
HOLTUG LARS	Director	Mar 02 '26	Proposed Sale	242.09	2,100	508,389		Mar 02 04:32 PM
SPROGOE KENNETT	Officer	Mar 02 '26	Proposed Sale	242.09	10,800	2,614,572		Mar 02 04:27 PM
JENSEN FLEMMING STEEN	Officer	Mar 02 '26	Proposed Sale	242.09	10,800	2,614,572		Mar 02 04:23 PM
Cha Albert	Director	Mar 02 '26	Proposed Sale	242.09	2,100	508,389		Mar 02 04:18 PM
MIKKELSEN JAN MOLLER	Officer	Jan 13 '26	Proposed Sale	211.99	86,860	18,413,631		Jan 13 02:01 PM
JENSEN MICHAEL WOLFF	Officer	Dec 04 '25	Proposed Sale	208.10	10,000	2,081,019		Dec 04 05:07 PM
Jan Moller Mikkelsen	CEO	Dec 02 '25	Proposed Sale	210.85	100,000	21,085,000		Dec 02 05:04 PM
SPROGOE KENNETT	Officer	Dec 02 '25	Proposed Sale	209.32	10,000	2,093,222		Dec 02 04:54 PM
JENSEN FLEMMING STEEN	Officer	Dec 02 '25	Proposed Sale	205.85	10,000	2,058,454		Dec 02 04:43 PM
SINGEL STINA	Officer	Dec 01 '25	Proposed Sale	209.54	218	45,680		Dec 01 02:30 PM

Ascendis Pharma A/S is a biopharmaceutical company, which engages in the development of drug candidates. It specializes in its TransCon technologies to develop new therapies that address unmet medical needs. The company was founded by Jan Moller Mikkelsen, Dirk Vetter, and Harald Rau on September 21, 2006 and is headquartered in Hellerup, Denmark.

PresidentMr. Jan Moller Mikkelsen

CFOMr. Scott T. Smith

Executive VPMs. Pedersen Anni Lotte Kirstine Sonderbjerg

Executive VPMr. Michael Wolff Jensen L.L.M.

Senior VPMr. Mads Bodenhoff

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

All the Features.Half the Price.

ASND

Ascendis Pharma A/S

Upgrade your Finviz experience

All the Features.
Half the Price.